期刊文献+

内蒙古东部地区宫颈癌及宫颈癌前病变的人群筛查研究 被引量:18

Population-based screening of cervical cancer and precancerous lesions among women from Eastern Area of Inner Mongolia
下载PDF
导出
摘要 目的探讨内蒙古东部地区妇女宫颈癌及宫颈癌前病变的疾病状况。方法本研究是以人群为基础的横断面筛查研究,2005—2010年间,选取内蒙古东部地区三个筛查点的18~69岁的妇女作为目标人群,采集其宫颈脱落细胞标本,细胞学诊断采用TBS2001分级系统,异常者进行阴道镜检,有病变者直接取活检明确诊断。细胞学阳性定义为意义不明确的非典型鳞状上皮细胞(ASCUS)以及更高度病变,以组织病理学为金标准,分析不同年龄组,地区和民族患者宫颈癌及宫颈上皮内瘤变(CIN)的发病趋势。结果①内蒙东部地区全人群、蒙族和汉族妇女异常细胞学(ASCUS+)的检出率分别为6.56%、8.03%和6.06%;其中蒙族妇女细胞学异常病变的检出率高于汉族妇女;②病理结果显示:内蒙东部地区宫颈上皮内瘤变(CIN1)的患病率为2.4%,>CIN2的患病率为1.47%,宫颈早浸癌的患病率为0.04%;蒙族妇女患病率较汉族高,通辽地区的患病率较呼盟和赤峰地区高。其中蒙族妇女各级病变的患病率分别为:CIN12.87%、>CIN21.80%、早期浸润癌0.10%;汉族分别为:2.25%、1.36%、0.03%。疾病年龄分布:CIN1现患率最高为35岁之前年龄组,>CIN2的高发年龄为40~49岁,宫颈癌的高发年龄为50~54岁。结论①内蒙东部地区蒙古族妇女宫颈癌及癌前病变的现患率高于汉族妇女;②在内蒙东部地区宫颈癌的筛查年龄段应涵盖30~55岁年龄组,其中40~55岁年龄组为重点人群,应在该年龄段加强宫颈癌的筛查。 Objective To investigate the prevalence of cervical cancer and precancerous lesions among women in eastern area of Inner Mongolia.Methods This is a population-based, cross-sectional screening study. Women aged 18yr to 69yr were recruited from May 2005 to May 2010.Cervical exfoliated cells were collected for Thinprep cytological testing (TCT) for each subject. Direct biopsies under colposcopy were taken if any abnormalities were found. TBS 2001 system was used for cytology diagnosIs, and positive results were defined as atypical squamous cell of undetermined significance (ASCUS) and more severe lesions. Disease burdens of cervical cancer and cervical intraepithelial neoplasia(CIN) were estimated by different age groups, areas and nationalities.Results ① The prevalence of abnormal cytological result(ASCUS+)for general population, Mongolian women and Han women in East Inner Mongolia was 6.56%, 8.03% and 6.06%, respectively. Generally, Mongolian women showed a higher prevalence of abnormal cytological results than Han women. ② The pathological results showed that the prevalence of CIN1, CIN2+ and early invasive carcinoma in East Inner Mongolia was 2.4%, 1.47% and 0.04%,respectively. Mongolian women suffered a heavier burden than Han women, and Tongliao showed a higher prevalence than Humeng and Chifeng areas. Specifically, the prevalence of CIN1, CIN2+ and early invasive carcinoma was 2.87%, 1.80% and 0.10% for Mongolian women, and 2.25%, 1.36% and 0.03% for Han women. The highest prevalence of CIN1, CIN2+ and early invasive carcinoma was observed in young age group before 35yr, 40-49yr group and 50-54yr group, respectively.Conclusions ① The prevalence of cervical cancer and cervical- precancerous lesions in Mongolian women were higher than Han Chinese women in East Inner Mongolia.② This study indicates that the age group of 30-55 yrs should be included into cervical cancer and precancerous lesions screening, and 40-55 ys should be the high-risk population for high grade precancerous lesions screening.
出处 《中国妇产科临床杂志》 2012年第3期190-193,共4页 Chinese Journal of Clinical Obstetrics and Gynecology
基金 内蒙古地区子宫颈癌的预防及癌前病变的干预(20070501)
关键词 宫颈癌 人群筛查 薄层液基细胞学 内蒙古 cervical cancer population-based screening ThinPrep liquid based cytology Inner Mongolia
  • 相关文献

参考文献13

  • 1Ferlay J, Shin HR, Bray F, er Incidence and Mortality No. 10. Available at: http: Jan 27, 2011. et al. GLOBOCAN 2008, Cane- Worldwide: IARC CancerBase //globocan. iarc. fr. Accessed.
  • 2卫生部肿瘤防治研究办公室.北京:中国恶性肿瘤死亡率资料汇编(1973-1975),1980:259.
  • 3李连弟,陈育德.中国恶性肿瘤死亡调查研究(1990-1992).北京:人民卫生出版社,2008.
  • 4Solomon D, Davey D, Kurman R, etal. The 2001 Bethesda system; terminology for reporting results of cervical cytology. JAMA, 2002, 287: 2114-2119.
  • 5Zhao FH, Lin MJ, Chen F, et al. Performance of high - risk human papillomavirus DNA testing as a primary screen for cervical cancer: a pooled analysis of individual patient data from 17 population- based studies from China. Lancet Oncol, 2010, 12: 1160-1171.
  • 6赵恩锋,鲍嫘,李超,宋磊,李亚里.近50年宫颈癌的发病趋势和临床特点分析(英文)[J].第一军医大学学报,2005,25(6):605-609. 被引量:27
  • 7赵方辉,乔友林.人乳头瘤病毒预防性疫苗的研究进展及应用前景[J].中华预防医学杂志,2009,43(7):640-643. 被引量:5
  • 8Moseicki AB. Impact of HPV infection in adolescent popula- tions. J Adolesc Health, 2005, 37 (6 Suppl):S3- 59.
  • 9Zhao FH, Tiggelaar SM, Hu SY, et al. A multi--center survey of age of sexual debut and sexual behavior in Chinese women: Suggestions for optimal age of human papillomavirus vaccination in China. Cancer Epidemiology (2012), doi: 10. 1016/j. canep. 2012, 01. 009.
  • 10WHO. Comprehensive Cervical Cancer Control: A Guide to Essential Practice. Geneva: World Health Organization, 2006.

二级参考文献57

  • 1Christopherson WM, Lundin FE Jr, Mendez WM, et al. Cervical cancer control: a study of morbidly and mortality trends over a twenty-one-year period. Cancer, 1976, 38 : 1357-1366.
  • 2Gissmann L, deVilliers EM, zur Hausen H. Analysis of human genital warts (condylomata acuminata) and other genital tumors for human papillomavirus type 6 DNA. Int J Cancer, 1982, 29: 143-146.
  • 3Villa LL, Costa RL, Petta CA, et aL High sustained efficacy of a prophylactic quadfivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer, 2006,95 : 1459-1466.
  • 4Joura EA, Leodolter S, Hemandez-Avila M, et al. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. Lancet, 2007, 369:1693-1702.
  • 5Tay EH, Garland S, Tang G, et al. Clinical trial experience with prophylactic HPV 6/11/16/18 VLP vaccine in young women from the Asia-Pacific regiotr Int J Gynaecol Obstet, 2008, 102: 275 -283.
  • 6Harper DM. Impact of vaccination with Cervarix ( trade mark) on subsequent HPV-16/18 infection and cervical disease in women 15-25 years of age. Gynecol Oncol, 2008, 110 ( 3 Suppl 1 ) : S11-17.
  • 7Descamps D, Hardt K, Spiessens B, et al. Safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for cervical cancer prevention: a pooled analysis of 11 clinical trials. Hum Vaccin , In press 2009.
  • 8Hildesheim A, Herrero R, Wacholder S, et al. Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial. JAMA, 2007,298:743-753.
  • 9Jit M, Choi YH, Edmunds WJ. Economic evaluation of human papillomavirus vaccination in the United Kingdom BMJ, 2008, 337 : a769.
  • 10Qiao YL, Sellors JW, Eder PS, et al. A new HPV-DNA test for cervical-cancer screening in developing regions: a cross-sectional study of clinical accuracy in rural China. Lancet Oncol, 2008, 9 : 929-936.

共引文献161

同被引文献147

引证文献18

二级引证文献126

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部